Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01239797 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

646

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Multiple Myeloma

Interventions

DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Dexamethasone (Oral)
DRUG: Dexamethasone (IV)
BIOLOGICAL: Elotuzumab (BMS-901608; HuLuc63)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]